Mytide Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Mytide Therapeutics, Inc. - overview
Established
2018
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2018 by co-founders Dale Thomas and Jason Norris, Mytide Therapeutics, Inc. operates as a peptide and biopolymer manufacturing and computational biology company for serious conditions, ranging from cancer to inflammatory disorders and infectious diseases. In March 2020, Mytide Therapeutics, Inc. raised USD 7 million in series A funding led by new investor Alloy Therapeutics, Inc.
, with participation from another new investor, Trog Hawley Capital. Returning investor Uncommon Denominator and the company's management also participated in the round. Mytide Therapeutics, Inc. offers automated peptide manufacturing technology, with analytics and machine learning, providing quoting, property calculator, order tracking, and a data analysis suite.
Its Rapid Automated Computation, Coupling, Cleavage, and Chromatography Execution platform provides computational biology that enables molecule identification and selection. The company will use the series A funding to scale its AI-enabled Gen2 platform and to support manufacturing for peptide and peptide conjugate applications for therapeutic discovery and personal peptide vaccines (PPV).
Current Investors
Uncommon Denominator, Alloy Therapeutics, Inc., Trog Hawley Capital
Primary Industry
Biotechnology
Sub Industries
Biopolymers, Bioinformatics
Website
www.mytide.io
Verticals
Artificial Intelligence, Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.